universal influenza a nanoparticle vaccine m2ehbc acam-flu-atm  (Acambis Inc)

Journal: ACS infectious diseases

Article Title: A perspective of nanoparticle universal influenza vaccines

doi: 10.1021/acsinfecdis.8b00206

Figure Lengend Snippet: (A) Polymer nanoparticle; (B) Virus like particle; (C) Gold nanoparticle; (D) Chemically assembled double-layered protein nanoparticle; (E) Naturally assembled protein nanoparticle (EMDB EMD-6332).

Article Snippet: 124 A phase I clinical trial of the universal influenza A nanoparticle vaccine, M2eHBc (ACAM-FLU-A™) sponsored by Acambis (later acquired by Sanofi Pasteur), generated interesting results.

Techniques:

Journal: ACS infectious diseases

Article Title: A perspective of nanoparticle universal influenza vaccines

doi: 10.1021/acsinfecdis.8b00206

Figure Lengend Snippet: Overview of nanoparticle universal influenza A vaccines.

Article Snippet: 124 A phase I clinical trial of the universal influenza A nanoparticle vaccine, M2eHBc (ACAM-FLU-A™) sponsored by Acambis (later acquired by Sanofi Pasteur), generated interesting results.

Techniques:

Journal: ACS infectious diseases

Article Title: A perspective of nanoparticle universal influenza vaccines

doi: 10.1021/acsinfecdis.8b00206

Figure Lengend Snippet: Nanoparticles with larger sizes over 100 nm are captured by dendritic cells from outside of lymphatic epithelia, in comparison, soluble protein antigen and smaller nanoparticles less than 10 nm are able to penetrate through lymphatic epithelia. Once antigens transported into lymph nodes via lymphatic vessels, they are presented to B cells and T cells by follicle dendritic cells. The larger nanoparticles are much more efficiently taken up by dendritic cells than smaller nanoparticles and potentially induce stronger and long-term specific immunity.

Article Snippet: 124 A phase I clinical trial of the universal influenza A nanoparticle vaccine, M2eHBc (ACAM-FLU-A™) sponsored by Acambis (later acquired by Sanofi Pasteur), generated interesting results.

Techniques:

Journal: ACS infectious diseases

Article Title: A perspective of nanoparticle universal influenza vaccines

doi: 10.1021/acsinfecdis.8b00206

Figure Lengend Snippet: The fabrications of fluorescent NP protein and fluorescent NP nanoparticle were described previously. (46) Mice were fed alfalfa-free diets for two weeks to reduce autofluorescence background before intramuscular injection with five micrograms of fluorescent antigen each mouse. Biodistributions of intramuscularly injected Alexa Fluor 700 succinimidyl ester dye-conjugated fluorescent NP nanoparticle and fluorescent soluble NP protein were analyzed in vivo using Perkin-Elmer IVIS Spectrum In Vivo Imaging System at the following time points: pre-injection, 0-hour post injection (hpi), 24-hpi and 48-hpi. (46) Mice injected with DPBS were used as negative control.

Article Snippet: 124 A phase I clinical trial of the universal influenza A nanoparticle vaccine, M2eHBc (ACAM-FLU-A™) sponsored by Acambis (later acquired by Sanofi Pasteur), generated interesting results.

Techniques: Injection, In Vivo, In Vivo Imaging, Negative Control